Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 680,800 shares, a growth of 300.2% from the December 31st total of 170,100 shares. Approximately 1.0% of the shares of the company are sold short. Based on an average trading volume of 348,300 shares, the short-interest ratio is currently 2.0 days.

Tiziana Life Sciences Stock Down 0.4 %

Tiziana Life Sciences stock traded down $0.00 during mid-day trading on Friday, hitting $0.69. 179,300 shares of the company's stock traded hands, compared to its average volume of 1,196,480. The firm has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.94. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74.

Institutional Trading of Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC lifted its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 24.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,387 shares of the company's stock after buying an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent reporting period.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.